Brian McGuinness
Corporate Officer/Principal bij Crescendo Biologics Ltd.
Oorsprong van het eerstegraads netwerk van Brian McGuinness
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom.
8
| Holding Company | Miscellaneous Commercial Services | 8 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Brian McGuinness via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Director of Finance/CFO Director/Board Member | |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
Index Ventures SA
Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland. | Investment Managers | Corporate Officer/Principal Private Equity Analyst | |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Director/Board Member | |
HOOKIPA PHARMA INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
ALMIRALL, S.A. | Pharmaceuticals: Major | Director/Board Member | |
Aleta Biotherapeutics, Inc.
Aleta Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aleta Biotherapeutics, Inc. engages in the immuno-oncology service that focuses on transforming cellular therapeutics. It allows broad spectrum of cancer indication to be targeted including currently intractable solid tumors. The company was founded by Paul Rennert and Roy Lobb and is headquartered in Natick, MA. | Miscellaneous Commercial Services | Director/Board Member | |
C4X DISCOVERY HOLDINGS PLC | Pharmaceuticals: Major | Chairman | |
The Bioindustry Association
The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012. | Miscellaneous Commercial Services | Director/Board Member | |
CIRCIO HOLDING ASA | Biotechnology | Director/Board Member | |
Karolinska Institutet | College/University | Corporate Officer/Principal | |
GE Healthcare Ltd. (United Kingdom)
GE Healthcare Ltd. (United Kingdom) Medical SpecialtiesHealth Technology GE Healthcare Ltd. provides transformational medical technologies and services which include icenter, AssetPlus, preventive maintenance, continuity, digital solutions and Unisys multi brand probe repair services. The firm offers magnetic resonance imaging, hemodynamic recording, EP recording, metabolic health and computed tomography. The company was founded on February 16, 1971 and is headquartered in Little Chalfont, the United Kingdom. | Medical Specialties | Corporate Officer/Principal | |
IMMUNOCORE HOLDINGS PLC | Biotechnology | Director/Board Member | |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Investment Managers | Private Equity Investor | |
Draupnir Bio ApS
Draupnir Bio ApS Pharmaceuticals: MajorHealth Technology Draupnir Bio ApS engages in the manufacture and distribution of biotechnological and pharmaceutical products. It also provides medical research services. The company was founded on April 4, 2017 and is headquartered in Risskov, Denmark. | Pharmaceuticals: Major | Chairman | |
University of Stockholm | College/University | Undergraduate Degree | |
Novavax AB
Novavax AB Pharmaceuticals: GenericHealth Technology Novavax AB is engaged in research and development of vaccines. Its products include Matrix and AbiSCO. The company was founded by Bror Morein in 1999 and is headquartered in Uppsala, Sweden. | Pharmaceuticals: Generic | Director/Board Member | |
Eluminex Biosciences (Suzhou) Ltd.
Eluminex Biosciences (Suzhou) Ltd. BiotechnologyHealth Technology Eluminex Biosciences (Suzhou) Ltd. is a privately held biotechnology company located in Suzhou, China. Eluminex Biosciences is committed to developing innovative pharmaceuticals, drug delivery systems, and regenerative tissue for significant unmet vision-threatening or lifestyle limiting ophthalmic diseases in various markets. The Chinese company focuses on ophthalmology and recombinant human collagen technology, with a goal to become a leading healthcare company in developing irreversible loss of optical quality of the cornea due to disease or damage, diabetic macular edema, and wet age-related macular degeneration. The company was founded in 2020 by Jin Zhong Zhang, who has been the CEO since then. | Biotechnology | Director/Board Member | |
Shanghai Rarestone Health Tech Group Co. Ltd.
Shanghai Rarestone Health Tech Group Co. Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Rarestone Health Tech Group Co. Ltd. is a Chinese company that focuses on rare disease therapy and self-management information through internet information. The company is based in Huangpu, China. The company also operates and promote medical devices and communication platforms. The CEO of the company is Shawn Xiang. | Pharmaceuticals: Major | Director/Board Member | |
Innoforce Pharmaceuticals Co. Ltd.
Innoforce Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Innoforce Pharmaceuticals Co. Ltd. is a bioinnovation-enabling corporation located in the Hangzhou Bay Biotech Valley within the Hangzhou Airport Economic Demonstration Area. The founders and core management team have extensive international experience and expertise in technology innovation, product development, and business operations. The Chinese company's first phase of the campus covers 21 acres, including biologic process development laboratories, scale-up and R & D labs, and manufacturing facilities for protein, cell, and gene therapies. The company was founded in 2018 by Guo-Liang Yu, Yuling Li, and Zhenhua Wu. Dewan Zeng has been the CEO of the company since 2023. | Pharmaceuticals: Major | Director/Board Member | |
Kira Pharmaceuticals (Hong Kong) Ltd.
Kira Pharmaceuticals (Hong Kong) Ltd. Pharmaceuticals: MajorHealth Technology Kira Pharmaceuticals (Hong Kong) Ltd. manufactures pharmaceuticals. The private company is based in Hong Kong, Hong Kong. | Pharmaceuticals: Major | Director/Board Member | |
MEDx Translational Medicine Co., Ltd.
MEDx Translational Medicine Co., Ltd. Medical DistributorsDistribution Services MEDx Translational Medicine Co., Ltd. is a leading Chinese innovative company in companion diagnostics and precision medicine in China. The company is based in Suzhou, China. MEDx collaborates with hundreds of world-renowned pharmaceutical companies and has been rewarded with many certifications, including China CNAS, ISO17025, and US CAP ISO 13485, among others. The company was founded in 2013 as Qiagen Translational Medicine Co., Ltd. With comprehensive technology platforms, high-quality systems, and strong IVD R&D experience, MEDx offers integrated solutions from biomarker discovery to patient stratification for drug clinical trials, IVD/CDX R&D, and commercialization. The company was founded in 2013 by Ya Fei Zhang, who has been the CEO since then. | Medical Distributors | Director/Board Member | |
ABLYNX | Biotechnology | Public Communications Contact | |
RioTech Pharmaceuticals Ltd.
RioTech Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology RioTech Pharmaceuticals Ltd. develops novel therapeutic drugs for hepatitis C virus. The company was founded on Nov 5, 2001 by Graham Foster, Adrian V. S. Hill, Peter Karayiannis, Howard David Thomas and Mark R. Thursz and is headquartered in Horsham, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | Pharmaceuticals: Major | Chairman | |
Touchstone Innovations Investment Management Ltd.
Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Investment Managers | Director/Board Member | |
Columbia University Medical Center | College/University | Corporate Officer/Principal | |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Daiichi Sankyo, Inc. manufactures and supplies pharmaceutical products. It markets therapies in hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma. The company was founded in 2006 and is headquartered in Basking Ridge, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Albert Einstein College of Medicine, Inc. | College/University | Doctorate Degree | |
CytoKi Pharma ApS
CytoKi Pharma ApS Miscellaneous Commercial ServicesCommercial Services CytoKi Pharma ApS engages in the research and experimental development within biotechnology. It develops therapeutics for serious tissue and organ injuries. The company was founded by Rasmus Jørgensen on June 12, 2019 and is headquartered in Vaerlose, Denmark. | Miscellaneous Commercial Services | Director/Board Member | |
Vandria SA
Vandria SA Pharmaceuticals: MajorHealth Technology Vandria SA is a Swiss-based company that specializes in mitochondrial therapeutics. The company is based in Lausanne, Switzerland. The company is developing mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its lead program, VNA-318, is a brain-penetrant, patent-protected, mitophagy inducer that has shown to improve memory and learning and to have strong disease-modifying effects in models of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Vandria is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases, as well as a separate program that targets ferroptosis. The company was founded by Patrick Aebischer, Chris Rinsch, and Johan Auwerx in 2021 and has raised $20.60m in venture finance. Klaus Dugi has been the CEO of the company since 2021. | Pharmaceuticals: Major | Director/Board Member | |
IP Group Plc /Venture Capital/
IP Group Plc /Venture Capital/ Investment ManagersFinance IP Group Plc /Venture Capital/ (IP Group) is a venture capital subsidiary of IP Group Plc founded in 2001. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
NanoDimension Management Ltd.
NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town. | Investment Managers | Private Equity Investor | |
TopiVert Ltd.
TopiVert Ltd. BiotechnologyHealth Technology TopiVert Ltd. develops topical treatments for inflammatory diseases of the eye and gut. Its application is used in the treatment of asthma, chronic obstructive pulmonary disease, and cystic fibrosis and other inflammatory diseases of the lungs. The company was founded by Eric Charles Meldrum in 2011 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
Escuela de Organización Industrial | College/University | Masters Business Admin | |
University of Barcelona | College/University | Doctorate Degree | |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member | |
Aravis AG
Aravis AG Investment ManagersFinance Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland. | Investment Managers | Private Equity Investor | |
SYNAIRGEN PLC | Pharmaceuticals: Major | Director/Board Member | |
Chronos Therapeutics Ltd.
Chronos Therapeutics Ltd. BiotechnologyHealth Technology Chronos Therapeutics Ltd. manufactures drugs. It pursuing innovative therapeutics for age-related diseases through the joint efforts of experts in medical research, drug discovery and business development. The company was founded in 2009 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member | |
OrthoMimetics Ltd.
OrthoMimetics Ltd. Medical SpecialtiesHealth Technology Orthomimetics brings a new dimension to the treatment of joints damaged through sport or other orthopaedic trauma. Its heritage is a trans-Atlantic collaboration between two world-leading academic institutions, the University of Cambridge and the Massachusetts Institute of Technology (MIT), who have each contributed 30 years of experience to the repair of bone and soft tissues respectively. The harnessing of their expertise into viable therapeutic medical products is the foundation of Orthomimetics. | Medical Specialties | Corporate Officer/Principal | |
Hybrid BioSystems Ltd.
Hybrid BioSystems Ltd. Miscellaneous Commercial ServicesCommercial Services Hybrid is an Oxford Biotechnology Company focused on revolutionizing viral vaccines with its patented vaccine delivery technologies. Hybrid has an established and well equipped laboratory located at Cherwell Innovation Centre in Oxford shire, which houses both its corporate research facility and contract research services. Using a mixed product and platform business model it is developing its in-house lead products towards phase I/II proof of concept clinical trials as well as furthering its partnerships with leading pharmaceutical and biotechnology companies. Hybrid's experienced scientific and management team has reached this late stage of development through a highly efficient use of grant funding and revenues, together with minimal seed funding. With its unparalleled expertise in the field of viral steal thing technologies, The firm is also able to offer general and bespoke virology services, including high-quality adenovirus production and purification. Hybrid BioSystems uses iLabber electronic lab books for maximum IP protection and secure data storage. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Shanghai Jiao Tong University | College/University | Undergraduate Degree |
Statistieken
Internationaal
Verenigd Koninkrijk | 19 |
Verenigde Staten | 8 |
China | 6 |
Zwitserland | 5 |
Spanje | 5 |
Sectoraal
Health Technology | 30 |
Consumer Services | 8 |
Finance | 7 |
Commercial Services | 6 |
Process Industries | 2 |
Operationeel
Director/Board Member | 64 |
Corporate Officer/Principal | 24 |
Private Equity Investor | 5 |
Independent Dir/Board Member | 5 |
Chairman | 5 |
Sterkste connecties
Insiders | |
---|---|
Graziano Seghezzi | 26 |
Gilles Nobécourt | 19 |
Marietta Wu | 19 |
Eva-Lotta Allan | 17 |
Daniel Bach | 13 |
Theodora Caroline Harold | 10 |
Igor Matushansky | 7 |
Kevin Johnson | 1 |
- Beurs
- Insiders
- Brian McGuinness
- Bedrijfsconnecties